Cargando…
A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes
Non-alcoholic steatohepatitis is frequently associated with diabetes and may cause progressive liver disease. Current treatment options are limited. Here we report on a prospective, randomised, double-blind, placebo-controlled trial of two doses of HTD1801 (berberine ursodeoxycholate, an ionic salt...
Autores principales: | Harrison, Stephen A., Gunn, Nadege, Neff, Guy W., Kohli, Anita, Liu, Liping, Flyer, Abbey, Goldkind, Lawrence, Di Bisceglie, Adrian M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448729/ https://www.ncbi.nlm.nih.gov/pubmed/34535644 http://dx.doi.org/10.1038/s41467-021-25701-5 |
Ejemplares similares
-
Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia
por: Di Bisceglie, Adrian M., et al.
Publicado: (2020) -
The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review
por: Xiang, Zun, et al.
Publicado: (2013) -
Structure of proof of concept studies that precede a nonalcoholic steatohepatitis development program
por: Williams, RN, et al.
Publicado: (2016) -
Berberine Reduces Neurotoxicity Related to Nonalcoholic Steatohepatitis in Rats
por: Ghareeb, Doaa A., et al.
Publicado: (2015) -
Berberine ameliorates non-alcoholic steatohepatitis in ApoE(−/−) mice
por: Yang, Jin, et al.
Publicado: (2017)